GLASGOW, Scotland & PITTSFIELD, Mass.--(BUSINESS WIRE)--Chemify and Prepaire™ Labs today announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform.

苏格兰格拉斯哥和马萨诸塞州皮茨菲尔德。-（商业新闻）——Chemify和Prepaire™ 实验室今天宣布，将与另外一个项目扩大合作伙伴关系，以应对持续的阿片类药物危机，并开发一类新型的数字发现的非成瘾性阿片类药物作为疼痛调节剂，以及通过将Chemify的突破性可编程化学平台与Prepaire的集成新型开放合作药物发现平台相结合，直接解决阿片类药物成瘾的药物。

The project, named Toxifree, comes in response to the FDA’s Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response..

该项目名为ToxinFree，是为了回应FDA药物评估与研究中心（CDER）的要求，该中心要求制药商和研究人员开发兴奋剂使用障碍的治疗方法，希望解决成瘾危机应对中的一个重大差距。。

After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform..

经过成功的初步合作，Chemify和Prepaire现在的目标是利用Chemify的化学计算技术，该技术可以使用化学编程语言和Prepaire的高级开放式结构药物开发平台，根据需要自动集成设计，发现和合成复杂分子。。

Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products..

根据这一合作关系的条款，Chemify将设计和发现新的化合物，以识别阿片类药物衍生的命中，并将其进一步开发为候选药物。Chemify将为每个开发的分子获得至少3000万美元的付款和预先协商的，成功驱动的临床和监管里程碑，以及任何产生的产品的单位数字版税。。

Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis..

Chemify创始人兼首席执行官、格拉斯哥大学Regius化学教授Lee Cronin拥有丰富的经验，领导研究工作，为阿片类药物危机制定解决方案。克罗宁领导的团队赢得了多项美国国立卫生研究院奖挑战赛，包括因设计、发现和自动合成下一代更安全、无成瘾的候选药物以帮助解决阿片类药物危机而获得亚军。。

'We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication.

“我们非常高兴将Chemify的分子设计，发现和合成技术与集成的Prepaire平台相结合，以扩大我们的合作，并创建一种完全集成的数字驱动药物发现方法。通过这种合作关系，我们正在开创一个新的疼痛调节发现计划，旨在解决全球对更好和非成瘾性止痛药的需求。

With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need,' said Professor Lee Cronin, Chemify's Founder and CEO..

Chemify的创始人兼首席执行官李·克罗宁（LeeCronin）教授说，凭借我们在化学计算指导下的独特设计方法，我们正在利用进化方法发现新化合物，以解决这一毁灭性和关键的医疗保健需求。。

'Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators.

“我们与Chemify的合作关系使我们的发现平台能够直接与Chemify的化学空间探索方法相结合，使我们能够获得否则无法获得的新型化学物质。随着我们合作的进展，我们的目标是建立一种综合方法，该方法可用于新型疼痛调节剂以外的更多适应症。

There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder,' said Dr Vicent Ribas, Prepaire’s Co-Founder..

目前还没有任何批准的治疗方法来帮助解决阿片类药物成瘾问题，近年来阿片类药物的使用激增。Prepaire的联合创始人Vicent Ribas博士说，本FDA指南的目的是协助临床试验设计开发新药，以支持治疗中度至重度可卡因使用障碍，治疗中度至重度甲基苯丙胺使用障碍或治疗中度至重度处方兴奋剂使用障碍的适应症。。

About Chemputation

关于化学计算

Digital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible.

数字化学将计算原理应用于化学可编程化学，Chemify开发了基础基础设施，使化学发现和合成成为可能。像计算机程序一样，数字化学程序可以自动运行化学实验，制造新分子，并确保复杂的化学配方始终可访问且完全可重复。

Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety..

化学程序是一段精确的代码，允许完全透明和可靠的操作，允许在完全审核和安全的情况下实施AI和其他技术。。

About Chemify

关于Chemify

Based in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery.

总部位于格拉斯哥的Chemify是一家领先的化学数字化公司，为世界领先的制药、生物技术和工业合作伙伴提供了一个新分子和材料呈指数增长的空间。通过利用数十年的化学经验、硬件机器人技术和人工智能，Chemify的化学计算技术使公司能够访问药物发现、分子合成和材料发现的端到端工作流程。

Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.

Chemify由首席执行官李·克罗宁（LeeCronin）根据苏格兰格拉斯哥大学克罗宁数字化学实验室的概念进步创立。通过建立化学数字化的基础设施，Chemify正在重新设想化学研究、发现和制造，以加速化学领域的进步，并将重点放在医学和功能材料上，从而造福全人类。

To learn more about Chemify, visit Chemify.io..

要了解更多有关Chemify的信息，请访问Chemify.io。。

About Prepaire Labs

关于Prepaire实验室

Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases.

Prepaire Labs是一家开创性的医疗保健技术公司，专注于彻底改变药物发现和精准医学。通过深度学习和生物学的整合，Prepaire实验室建立了基于遗传，表型和临床数据的预测模型。这些模型形成了对疾病的潜在结构和生物学的看法。

Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes.

Prepaire实验室利用患者来源的诱导多能干细胞（iPSC），基因组编辑，高含量细胞表型分析和机器学习来创建体外疾病模型，优化遗传学，细胞类型，环境和多维数据收集，以提高人类临床结果的可预测性。

A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE. This will serve as the new fully automated LAAS (Lab As A Service) hub and provide clinical trials on a chip using latest microfluidic devices combined with the ability to print organoid bio-networks. Visit www.prepaire.com to learn more..

最先进的BSL3实验室将于2024年5月开放，位于阿联酋阿布扎比马斯达尔市。这将成为新的全自动LAAS（实验室即服务）中心，并使用最新的微流体设备结合打印类器官生物网络的能力，在芯片上提供临床试验。访问www.prepaire.com了解更多信息。。